Targeted delivery of platinum-based anticancer complexes

Curr Opin Chem Biol. 2013 Apr;17(2):175-88. doi: 10.1016/j.cbpa.2013.01.004. Epub 2013 Feb 7.

Abstract

The most widely used anticancer drugs are platinum-based. Their efficacy might be improved by carriers which can transport large numbers of Pt centres, shield the drug from premature activation, and/or deliver Pt specifically to cancer cells using vectors which recognise specific targets. We describe recent progress using functionalized carbon nanotubes (CNTs) and nanorods, hollow Prussian blue (HPB), magnetic iron oxide and gold nanoparticles, liposomes, nanogels and polymers, as well as active targeting by conjugation to biodegradable proteins and peptides (e.g. EGF, heparin, herceptin, somatostatin and TAT). Spatially targeted activation of Pt(IV) prodrugs using light is also a promising approach. Interestingly, use of these new delivery and targeting systems for platinum drugs can lead to species with unusual reactivity which can kill cancer cells by new mechanisms.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacokinetics
  • Cell Line, Tumor
  • Drug Delivery Systems / methods*
  • Humans
  • MCF-7 Cells
  • Nanostructures / administration & dosage*
  • Nanostructures / chemistry
  • Neoplasms / drug therapy
  • Neoplasms / metabolism
  • Organoplatinum Compounds / administration & dosage*
  • Organoplatinum Compounds / chemistry
  • Organoplatinum Compounds / pharmacokinetics

Substances

  • Antineoplastic Agents
  • Organoplatinum Compounds